Every cell in the human body speaks a native language: electricity. At Electrome, we’re decoding and harnessing this language to pioneer a new class of precision therapeutics—powered by the bioelectric code.
The Electrome: Biology’s Operating System
Biological systems run on a foundation of bioelectricity. Every neuron fires by changing the voltage across its membrane. Wound healing is guided by endogenous electric fields. Even gene expression and immune cell behavior are modulated by ion channel dynamics. This electrical code—the Electrome—is nature’s original information system, directing development, regeneration, and defense.
For decades, modern medicine has overlooked this layer of control. While pharmacology targets biochemical pathways, Electrome targets the electrical instructions that precede them.\
We believe this is the future of medicine: signal-based therapeutics that modulate biology without drugs, chemicals, or invasive procedures.
An Integrated Platform for Bioelectric Discovery
Electrome is the first vertically integrated platform built to map, test, and translate bioelectric signals into scalable, regulated therapies. We’ve unified three powerful components into a single discovery engine:
Electrome Hardware Platform
Our lab-scale stimulation hardware delivers programmable pulsed electromagnetic fields (PEMF), radiofrequency (RF), and low-frequency waveforms across a wide range of biological samples. It supports precision targeting of cells, tissues, or organoids via:
- Modular antennas and petri dish-sized stimulation zones
- Software-defined signal parameters: frequency, waveform, amplitude, modulation
- Signal validation sensors and environmental controls
- Multi-sample parallel testing with real-time monitoring
The platform transforms wet lab environments into high-throughput signal screening engines.
AI Discovery Engine
We use machine learning to discover therapeutic signals faster than ever before. The AI models:
- Analyze cell and tissue responses to thousands of bioelectrical signals
- Identify patterns in wound healing, inflammation, cancer inhibition, and beyond
- Suggest next-generation waveforms based on inferred bioelectric pathways
- Optimize signal combinations, dosage, and duration with adaptive reinforcement
By training on both lab data and public literature, our AI models grow smarter with every experiment.
Bioelectric Knowledge Graph
We’ve built a unified, indexed knowledgebase of:
- Cell types and bioelectric properties (ion channel expression, voltage profiles)
- Public and proprietary signal-effect relationships
- Published and experimental PEMF/RF datasets
- Clinical endpoints and regulatory mappings
This graph allows researchers and engineers to query the electrome—to search for signals that trigger specific biological outcomes in specific cells or tissues.
From Lab Bench to Clinical Use
While many platforms stay in discovery mode for years, Electrome was designed from the start with translation in mind. Our first therapy—for pain and inflammation—is ready for market with a regulatory path via FDA 510(k) clearance, grounded in substantial equivalence to cleared devices like SofPulse® and ActiPatch®.
We are positioned to generate revenue in year one while expanding into new indications across:
- Chronic wounds and post-surgical recovery
- Neuropathic pain and peripheral nerve repair
- Autoimmune modulation and long COVID
- Oncology (immune priming and apoptosis induction)
- Infectious disease (targeted bacterial inhibition)
Our approach enables rapid iteration: screen in vitro, validate in vivo, scale to human trials—faster than traditional drug pipelines.
The Signal Is the Drug™
This is more than a metaphor. Our goal is to build a new therapeutic modality where electromagnetic signals are encoded with therapeutic intent—dosed, delivered, and regulated like molecular drugs, but with:
- No systemic side effects
- No toxicity
- No need for cold chain or complex manufacturing
- Potential to impact previously untreatable conditions
Just as CRISPR decoded the genome, Electrome is decoding the bioelectricome—and using it to write a new chapter in medicine.
Join Us
We are assembling the world’s first end-to-end electroceutical discovery and delivery platform. Whether you are an investor, clinician, scientist, or strategic partner:
The signal is clear. The time is now. The Electrome is the future.